Unbound MEDLINE

Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed to treat depression and a broad range of other comorbidities. The increased use of SSRIs in patients with various comorbidities treated with different drugs engenders the risk of pharmacokinetic drug interactions via cytochrome P450 (CYP450) enzymes inhibition. In the present review, we provide an overview of documented clinically significant drug interactions between SSRIs and other drugs co-prescribed in psychiatric patients for the same or other diseases. We further discuss the significance of drug interactions in the era of pharmacogenomics to underline the need for using information on both genotype and drug interactions towards implementing better clinical outcomes through personalized medicine.

Links

  • Publisher Full Text

    • Authors

    Manolopoulos VG, Ragia G, Alevizopoulos G

    Institution

    Laboratory of Pharmacology, Medical School, Democritus University of Thrace, and Clinical Pharmacology Unit, Academic General Hospital of Alexandroupolis, Alexandroupolis, Greece. emanolop@med.duth.gr

    Source

    Drug metabolism and drug interactions 27:1 2012 pg 19-31

    MeSH

    Animals
    Cytochrome P-450 Enzyme System
    Drug Interactions
    Drug Toxicity
    Humans
    Individualized Medicine
    Mental Disorders
    Polymorphism, Genetic
    Serotonin Uptake Inhibitors
    Smoking

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    22718622